ALK Positive UK成立于2018年,是一家注册慈善机构,其基本宗旨是为ALK阳性肺癌患者提供支持、赋权和倡导。该慈善机构定期对其成员进行调查,以收集有关他们诊断和治疗的各个方面的数据。这项2021年11月的调查在线分发给ALK Positive UK支持团体社区...
Method: In 2021, members of the charity ALK POSITIVE LUNG CANCER (UK) completed anonymised surveys to gather real-world data about their treatment. Results: Data were gathered on the prescribing of blood thinners (n = 127);frequency of brain MRI scans (n = 123);prescribing bone strengthening...
Anaplastic lymphoma kinase (ALK) is a potent oncogenic driver in lung cancer. ALK tyrosine kinase inhibitors yield significant benefit in patients with ALK fusion-positive (ALK+) lung cancers; yet the durability of response is limited by drug resistance. Elucidation of on-target resistance mechanisms...
2. Mok T, Camidge DR, et al. Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study. Ann oncology: Off J...
Real-World Treatment Patterns and Effectiveness of Subsequent Treatments Following First-line (1L) Brigatinib for Patients with Anaplastic Lymphoma Kinase Positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) from ALTA-1L ALTA-1L 中ALK+NSCLC 患者一线接受布格替尼治疗后后续治疗的真实世界治疗模式和有效...
[2]Zhou F, Guo H, Xia Y, et al. The changing treatment landscape of EGFR-mutant non-small-cell lung cancer. Nat Rev Clin Oncol. 2025 Feb;22(2):95-116. [3]Solomon BJ, Liu G, Felip E, et al. Lorlatinib Versus Crizotinib in Patients With Advanced ALK-Positive Non-Small Cell Lu...
Evaluating the Optimal TKI for Patients With ALK Positive Advanced Non-Small-Cell Lung Cancer (aNSCLC) in the First Line (1L) Setting: An Updated Systematic Literature Review (SLR) and Network MetaAnalysis (NMA) . 2024 ISPOR Europe. [3] Solomon BJ, Liu G, Felip E, et al. Lorlatinib ...
First-line crizotinib versus chemotherapy in ALK-positive lung cancer N Engl J Med, 371 (2014), pp. 2167-2177 doi:10.1056/NEJMoa1408440 CrossrefView in ScopusGoogle Scholar 8. B.J. Solomon, D.-W. Kim, Y.-L. Wu, et al. Final overall survival analysis from a study comparing first-li...
What do you do for the patient with ALK (anaplastic lymphoma kinase)-positive lung cancer who has received crizotinib and had benefit from crizotinib, but then has disease progression? This is an emerging area and all the answers are not in, but I would like to share with you what I and...
FDA approves ensartinib for ALK-positive locally advanced or metastatic non-small cell lung cancer. News release.注:本文旨在介绍医药健康研究,不作任何用药依据,具体用药指引,请咨询主治医师。如有需要可以咨询一下香港登越药业,专业提供各类进出口服务。 送TA礼物 1楼2025-02-20 11:33回复 ...